Guide price only. Final cost is confirmed after assessment.
At London Cartilage Clinic, our pioneering Stem Cell / Medicinal Signaling Cell hip therapy utilises Mesenchymal Stem Cells / Medicinal Signaling Cells (MSCs) to offer non-surgical solutions for hip joint conditions. This innovative approach focuses on the natural regenerative capabilities of MSCs, providing a promising alternative to traditional hip surgeries. Our treatment aims to enhance joint function, alleviate pain, and improve overall mobility in patients experiencing hip joint issues.
Reviewed byProfessor Paul Lee MBBch, FRCS (Tr & Orth), PhDCartilage and joint preservation expertise
MSCs are uniquely adept at regenerating hip joint tissues, including cartilage and bone. They are particularly beneficial for conditions like hip osteoarthritis, where they can significantly slow down joint degradation and stimulate the repair of damaged tissues. This therapy is ideal for patients seeking to preserve their hip joint and delay or avoid the need for hip replacement surgery.
Our treatment involves harvesting MSCs from the patient's body, concentrating these cells, and then accurately injecting them into the affected hip joint. This minimally invasive procedure stimulates the body's own repair mechanisms, facilitating the regeneration of hip joint tissues and leading to a quicker and more natural recovery process.
MSC therapy has shown significant promise in treating various hip joint conditions, including osteoarthritis, labral tears, and avascular necrosis. By focusing on the natural regeneration of hip joint tissues, our therapy offers a cutting-edge alternative to more invasive surgical options.
You may have more options than you think
At London Cartilage Clinic we follow a structured clinical framework across four areas of treatment. Before recommending a single procedure, we assess which combination of approaches gives you the best outcome.
Protect what you have. Slow degeneration and manage symptoms.
Fix specific damage. Torn tissue, unstable joints, structural problems.
Rebuild lost tissue. Biological treatments that stimulate new growth.
When other options are exhausted. Joint replacement as a last resort.
Explore the full range of treatments available for your joint. Each hub page shows every option we offer, organised by clinical approach.
MSC therapy is effective in treating a range of hip conditions, including osteoarthritis, labral tears, and avascular necrosis, among others. It offers a regenerative approach to hip joint preservation and repair.
The time to see improvements can vary depending on the individual's condition and severity. However, many patients report experiencing a reduction in pain and increased mobility within weeks to months after treatment.
While MSC therapy can provide long-lasting relief and tissue regeneration, it is not always a permanent solution. Ongoing research and patient follow-ups help us understand the long-term efficacy of this treatment.
As with any medical procedure, there are risks, but MSC hip therapy is generally considered safe, particularly as it uses the patient's own cells, greatly reducing the risk of adverse reactions.
Still have more specific concerns?
Free Discovery CallLondon Cartilage Clinic
Clinical updates, cartilage treatment guidance, and recovery-focused articles from our specialist team.
A talar osteochondral defect damages cartilage and subchondral bone at the ankle joint. Cartilage lacks blood supply and cannot repair itself; the defect will not heal naturally without intervention.
MACI simplifies cartilage repair by seeding cultured chondrocytes directly onto a collagen membrane in the laboratory, eliminating the need for periosteal patch harvest and intraoperative cell injection—steps that caused periosteal hypertrophy in up to 25% of classic autologous chondrocyte implantation cases.
ChondroFiller is a collagen scaffold that gels on injection and recruits the body's progenitor cells, regenerating hyaline cartilage; published data show average functional gains of 30 points with reoperation rates of 3–8% across 19,000 procedures.
